Skip to content
Menu Close
Close button
Go back to News

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

Upstream Bio has raised another $200 million to go through Phase II studies and prepare for late-stage trials of an ex-Astellas monoclonal antibody in anticipation of competition with AstraZeneca and Amgen’s asthma drug Tezspire.

upstream bio